Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 0 · 0%High 0 · 0%

Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Methylnaltrexone may leads to higher adverse events compared with placebo (low certainty).

1 finding from 1 review

Serious adverse eventsi · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Methylnaltrexone may leads to lower serious adverse eventsi compared with placebo (low certainty).

1 finding from 1 review

Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

Methylnaltrexone lower dose showed no clear difference in adverse events compared with higher dose (low certainty).

1 finding from 1 review

Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction

The review found no eligible studies for this question.

1 finding from 1 review